Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing and commercializing proprietary pharmaceuticals that improve the treatment of cancer and other life-threatening illnesses.
15984
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-15984,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1200,qode-theme-ver-18.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.5,vc_responsive
company featured image

Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing and commercializing proprietary pharmaceuticals that improve the treatment of cancer and other life-threatening illnesses.

 

Cantex’s pipeline has two product candidates in clinical development for diseases where innovative and more effective treatments are greatly needed.

 

READ MORE

pipeline featured image

DSTAT (formerly known as CX-01) for the treatment of acute lung injury (ALI) in COVID-19 patients and acute myeloid leukemia (AML)

 

Dicopp® for the treatment of metastatic pancreatic cancer, recurrent/refractory multiple myeloma, and recurrent pediatric sarcoma.

 

READ MORE

doctor viewing vaccine

April 2020 – Chimerix, Exclusive Licensee of Cantex’ Lead Product DSTAT, has Announced Initiation of a Phase 2/3 Study of DSTAT, Formerly Known as CX-01, in Acute Lung Injury for Patients with Severe COVID-19.
READ MORE

 

July 2019 – Chimerix Announces Exclusive Worldwide License of Phase 3 Ready CX-01 for Development in Acute Myeloid Leukemia.
READ MORE

DSTAT (formerly known as CX-01) for the treatment of acute lung injury (ALI) in COVID-19 patients and acute myeloid leukemia (AML)